UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Liver international, ISSN 1478-3223, 01/2009, Volume 29, Issue 1, pp. 1 - 8
Antiviral therapy | cirrhosis | hepatocellular carcinoma | Cirrhosis | Hepatocellular carcinoma | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepatitis B - physiopathology | Global Health | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Hepatitis C - epidemiology | Humans | Hepatitis B - drug therapy | Hepatitis B - epidemiology | Hepatitis C - physiopathology | Liver cancer | Antiviral agents | Transplantation of organs, tissues, etc | Hepatitis C | Health aspects | Public health | Hepatitis B | Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 02/2018, Volume 38, Issue S1, pp. 2 - 6
epidemiology | alcoholic liver disease | NAFLD | screening | hepatitis B | hepatitis C | ALT | chronic liver disease | NASH | cirrhosis | hepatocellular carcinoma | Hepatitis C | Epidemiology | Liver cirrhosis | Public health | Medical personnel | Health care | Cirrhosis | Screening | Liver diseases | Liver | Viruses | Morbidity | Diseases
Journal Article
Liver international, ISSN 1478-3223, 02/2012, Volume 32, Issue 1, pp. 88 - 102
boceprevir | ribavirin | NS5A inhibitors | telaprevir | polymerase inhibitors | protease inhibitors | pegylated interferon | Boceprevir | Protease inhibitors | Pegylated interferon | Polymerase inhibitors | Telaprevir | Ribavirin | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Serine Proteinase Inhibitors - administration & dosage | Disease Eradication | Drug Administration Schedule | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Proline - therapeutic use | Time Factors | Drug Resistance, Viral - drug effects | Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 01/2011, Volume 31, Issue 1, pp. 68 - 77
boceprevir | interferon‐λ | ribavirin | telaprevir | polymerase inhibitors | protease inhibitors | pegylated interferon | IL‐28B | Boceprevir | Protease inhibitors | Pegylated interferon | IL-28B | Polymerase inhibitors | Telaprevir | Interferon-λ | Ribavirin | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Polyethylene Glycols - metabolism | Interferon-alpha - metabolism | Virus Replication - drug effects | Proline - analogs & derivatives | Standard of Care | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Proline - therapeutic use | Drug Therapy, Combination - methods | Signal Transduction - drug effects | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | Liver cancer | Proteases | Biological response modifiers | Hepatitis C | Drug therapy | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 5 - 6
Journal Article
Liver international, ISSN 1478-3223, 02/2013, Volume 33, Issue 1, pp. 93 - 104
sofosbuvir | faldaprevir | simeprevir | ribavirin | NS5A inhibitors | NS5B polymerase inhibitors | protease inhibitors | asunaprevir | daclatasvir | Daclatasvir | Simeprevir | Protease inhibitors | Faldaprevir | Asunaprevir | Ribavirin | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Models, Molecular | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Hepacivirus - enzymology | Serine Proteinase Inhibitors - chemistry | Antiviral Agents - chemistry | Serine Proteinase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Drug Design | Molecular Structure | Drug Therapy, Combination | Viral Nonstructural Proteins - antagonists & inhibitors | Interferon | Biological response modifiers | Hepatitis C virus | Proteases | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9865, pp. 468 - 475
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | General aspects | Viral hepatitis | Infectious diseases | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Other diseases. Semiology | Immunohistochemistry | Severity of Illness Index | Adenine - analogs & derivatives | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Safety Management | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - administration & dosage | Dose-Response Relationship, Drug | Tenofovir | Hepatitis B virus - drug effects | Organophosphonates - administration & dosage | Hepatitis B, Chronic - drug therapy | Time Factors | Adult | Female | Biopsy, Needle | Hepatitis B, Chronic - pathology | Complications and side effects | Dosage and administration | Research | Drug therapy | Liver cirrhosis | Risk factors | Hepatitis B | Hepatitis | Liver cancer | Consent | Mortality | Infections | Histology | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 02/2014, Volume 34, Issue 1, pp. 60 - 68
antiviral potency | direct‐acting antivirals | pills burden | safety | resistance | Resistance | Safety | Antiviral potency | Direct-acting antivirals | Pills burden | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Simeprevir | Antiviral Agents - pharmacology | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Hepacivirus - genetics | Genotype | Clinical Trials as Topic | Drug Approval | Sulfonamides - pharmacology | Uridine Monophosphate - pharmacology | Drug Therapy, Combination - adverse effects | Drug Therapy, Combination - methods | Drug Therapy, Combination - trends | Time Factors | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Thiazoles - pharmacology | Oligopeptides - pharmacology | Sofosbuvir | Genetic aspects | Interferon | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
9.
Full Text
Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?
Liver international, ISSN 1478-3223, 02/2018, Volume 38, Issue S1, pp. 7 - 13
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality | Index Medicus | Abridged Index Medicus
Journal Article